Multiple Doses of Cnty-101, an iPSC-Derived Allogeneic CD19 Targeting CAR-NK Product, Are Safe and Result in Tumor Microenvironment Changes Associated with Response: A Case Study
Indu Ramachandran,Sarah Rothman,Mariano Clausi,Kile Mcfadden,Brenda Salantes,Gloria Jih,Thomas Brigman,Sam Kelly,Matthew S Hall,Stephanie Yee,Iphigenia Koumenis,Poulomee Das,Jordan Briggs,Tori Braun,Ying Yuan,Elizabeth Devlin,Adrienne Farid,Nikolaus S. Trede,Tamara K. Moyo,Tahir Latif
